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TUBERCULOSIS CHEMOTHERAPY CENTRE, MADRAS 1
Previous reports from the Tuberculosis Chemotherapy Centre, Madras, have
established that ambulatory treatment of pulmonary tuberculosis with the combina-
tion of isoniazid and PAS, administered daily, yields satisfactory results. However,
in the usage of any unsupervised regimen, reliance must be placed on the co-opera-
tion of patients in self-administering their drugs. Irregularities in drug-taking, which
are not uncommon, may lead to unfavourable therapeutic results; this might be
avoided by supervised administration of the drugs. Daily supervision is clearly
impracticable in developing countries but regimens in which the drug is administered
intermittently-say, twice a week or less frequently-are, if effective, more likely
to gain general application.
This paper presents the results of a controlled study of a fully supervised inter-
mittent regimen of isoniazid (12.5-16.1 mg/kg body-weight, orally) plus streptomycin
(injected in a uniform dose of I g), given together twice weekly, compared with a
standard, unsupervised, daily, oral regimen of isoniazid (3.7-63 mg/kg body-weight)
plus sodium PAS (0.2-0.3 g/kg body-weight), given in two doses. The intermittent
regimen was at least as effective as the standard oral regimen, and although the
incidence of temporary giddiness in patients receiving this regimen was rather high,
this did not appear to have any long-term importance nor did it appear unduly to
affect the co-operation of the patients. These encouraging findings suggest a possible
change in the orientation of drug-administration for tuberculosis in developing
countries.
1The Centre is under the joint auspices of the Indian
Council of Medical Research (ICMR), the Madras State
Government, the World Health Organization (WHO) and
the Medical Research Council of Great Britain (MRC). The
members of the scientific staff of the Centre with major res-
ponsibility for the work reported here are: Dr Hugh Stott
(WHO), Senior Medical Officer; Dr J. J. Y. Dawson (WHO),
Dr C. V. Ramakrishnan (ICMR) and Dr S. Velu (Madras
Government), Medical Officers; Dr S. Devadatta (ICMR),
Assistant Medical Officer; Dr S. R. Kamat (ICMR), Senior
Research Officer; Dr J. B. Selkon (WHO), succeeded by
Dr E. M. Mackay-Scollay (WHO) in January 1962, and
Dr S. P. Tripathy (ICMR), Bacteriologists; Mr C. Naraya-
nan Nair (ICMR), Assistant Bacteriologist; Mr D. V. Krish-
namurthy (ICMR), Biochemist; Mr C. V. Jacob (ICMR) and
Miss S. Joseph (ICMR), Laboratory Research Assistants;
Mr K. L. Thomas (WHO), succeeded by Mr P. M. Hinchliffe
(WHO), Laboratory Technician; Mr K. Ramachandran
(ICMR) and Mr P. R. Somasundaram (ICMR), Statisticians;
and Mr B. Janardhanam (ICMR) and Mr N. Nataraja
(ICMR), Senior Assistant Statisticians.
The research of the Centre is guided by a Project Com-
mittee consisting of three ICMR representatives (Dr P. V.
Benjamin, Convenor, succeeded in July 1962 by Dr N. L.
Bordia, Dr J. Frimodt-Møller and Dr K. S. Sanjivi), the
Director of the ICMR (Dr C. G. Pandit), the Director of
Medical Services, Madras State (Dr V. R. Thayumanaswamy,
succeeded in November 1961 by Dr A. B. Marikar), a WHO
representative (appointed for each meeting), an MRC re-
presentative (appointed for each meeting) and the Senior
Medical Officer of the Centre (Dr Hugh Stott). The joint
secretaries are Mr D. Chakravarti, and Mr B. S. Verma
succeeded by Mr V. S. Talwar in April 1962. The MRC
(acting through its Tuberculosis Research Unit) is respon-
sible for advising WHO on the research in accordance with
plans prepared by the Project Committee. Close contact is
maintained between this Centre, Dr P. D’Arcy Hart (MRC
Tuberculosis Research Unit), Dr Wallace Fox (MRC Tuber-
culosis Research Unit), Dr Ian Sutherland (MRC Statistical
Research Unit) and Dr D. A. Mitchison (MRC Group for
Research on Drug Sensitivity in Tuberculosis).
The great majority of the patients in the present study
were referred to the Centre from the Government Tuber-
culosis Institute, Madras (Director: Dr M. A. Hamid) and
the Corporation Tuberculosis Clinic, Pulianthope (Medical
Officer in Charge: Dr V. S. Selvapathy).
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I. INTRODUCTION
The domiciliary chemotherapy of tuberculosis
conducted from outpatient clinics is widely prac-
tised in developing countries. Under such conditions
reliance is placed on the co-operation of the
patients in self-administering their drugs orally, a
practice which is known to have serious limitations
(see review by Fox, 1962). Although fully super-
vised daily chemotherapy has been conducted by
some (Stradling, 1957 ; Stradling & Poole, 1958 ;
Velu et al., 1961b ; Angel et al.; 1963 ; M. P. Flynn,
personal communication, 1963), this is clearly
impracticable as a general policy for developing
countries. If, instead, fully supervised chemo-
therapy could be given intermittently, for example,
twice a week or even less frequently, it would
become more generally applicable.
Previous studies at the Centre suggested a
rational basis for intermittent chemotherapy. In a
comparison of three regimens of isoniazid alone
with a standard regimen of isoniazid plus PAS
(Tuberculosis Chemotherapy Centre, 1960) it was
found that a moderate daily dosage of isoniazid
 (approximately 9 mg/kg body-weight) was more
effective when given in one dose than when given
in two doses. There was evidence that this was
because a high peak concentration of isoniazid
in the serum played a more important role in the
response to treatment than the maintenance of a
continuous inhibitory level of the drug (Ganga-
dharam et al., 1961b). It was therefore decided to
study a regimen which included a high dose of
isoniazid in which the interval between the doses
was extended. It seemed unlikely that the efficacy
would be seriously diminished by a limited degree
of intermittency, in view of the observation that
patients who showed irregularity (on the evidence
of urine tests for drug) in taking isoniazid in a
single large daily dose (approximately 14 mg/kg)
responded to treatment as well as those who were
completely regular (Tuberculosis Chemotherapy
Centre, 1963a, 1963b).
There is experimental evidence that isoniazid
given once weekly in the guinea-pig (Palmer et al.,
1956) or the mouse (Bloch, 1961) and streptomycin
given every five days in the guinea-pig (Corper &
Cohn, 1947) are effective in suppressing the
development of tuberculosis. Further, Grumbach
et al. (1952) have shown that an intermittent
regimen of a combination of streptomycin plus
isoniazid given to mice every three days is as
effective in controlling tuberculous infection as a
continuous daily regimen of the combination
given in one-third of the intermittent dosage.
In view of the findings in this Centre and the
above experimental evidence it was decided to
test the effectiveness of a combination of the two
most potent standard antituberculosis drugs,
namely isoniazid and streptomycin, given under
supervision twice weekly, the minimum interval
considered to offer substantial practical advantages
over regimens prescribed daily. Isoniazid was to
be given in a high dosage of approximately 14
mg/kg body-weight and streptomycin in a uniform
dose of 1 g, which, in view of the light weight
of the patients in Madras, is a higher dosage than
is customary elsewhere.
The detailed results of a controlled comparison
for a year of this supervised intermittent regimen
with the standard, unsupervised, daily regimen of
isoniazid plus PAS is presented in this report. The
bacteriological results at six and nine months have
already been reported in a preliminary communi-
cation (Tuberculosis Chemotherapy Centre, 1963c).
II. PLAN AND CONDUCT OF THE STUDY
The patients were drawn from the same area the earlier investigations. In particular they had
in Madras City as in previous investigations bacteriologically confirmed pulmonary tubercu-
(Tuberculosis Chemotherapy Centre, 1960, 1963a, losis, were aged 12 years or more, were judged to
1963b). As before, nearly all came from the poorest be co-operative (that is, were prepared to have
sections of the population and the great majority one year of domiciliary chemotherapy and to
were referred to the Centre from tuberculosis attend for subsequent follow-up) and had either
clinics where they had attended with symptoms. received no antituberculosis chemotherapy or had
They were admitted on the same criteria as in received it for not more than two weeks.
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PRETREATMENT INVESTIGATIONS
The pretreatment investigations included:
(1) A full clinical examination, including the
assessment of the general clinical condition, weight
(lb), and examination of the urine for albumin
and sugar.
(2) A full-plate postero-anterior chest radio-
graph and a standard series of tomographic cuts.
(3) The examination by direct smear and culture
of a minimum of four sputum specimens; two
were produced overnight in the home (collection
specimens) and two were expectorated under super-
vision at the Centre (supervised spot specimens).
(4) Tests of sensitivity to isoniazid, streptomycin
and PAS on two cultures.
(5) The determination of the rate of inactiva-
tion of isoniazid.
CHEMOTHERAPEUTIC REGIMENS
The two chemotherapeutic regimens studied
were an intermittent supervised regimen of isonia-
zid plus streptomycin given together twice weekly
(SHTW), and a standard, unsupervised, daily regi-
men of isoniazid plus PAS (PH). It was decided
to use a high dosage of isoniazid in the intermit-
tent regimen in order to achieve high peak serum
levels. The dosage selected was known to have
only a small risk of acute toxicity even when given
daily (Tuberculosis Chemotherapy Centre, 1963a,
1963b).
The dosages of isoniazid and PAS were graded
according to the patient’s weight (Table 1). If,
at a monthly examination, the patient had gained
weight and moved into a higher weight category,
the dosages were increased. The dosages were not
reduced for loss in weight. The streptomycin was
given in a uniform dosage of 1 g to all patients
 irrespective of weight. The details of the dosages
for patients weighing 100 lb (45.5 kg) were as
follows:
SHTW. Streptomycin sulfate by intramuscular
injection in a dose equivalent to 1 g of streptomy-
cin base plus isoniazid in a single oral dose of
650 mg (as three tablets containing 200 mg each
and one tablet containing 50 mg of isoniazid) ;
both drugs were given together twice weekly, at
intervals of three and four days alternately.
PH. Isoniazid 200 mg daily plus PAS (sodium
salt) 10 g daily ; the two drugs were given together
in eight cachets (four in the morning and four
in the evening), each cachet containing 25 mg of
isoniazid and 1.25 g of PAS (sodium salt).
For patients in the SHTW series, the mean
daily dosage of streptomycin at the start of treat-
ment was 27.0 mg/kg body-weight (range 18.2-53.7
mg/kg) and the mean initial dosage of isoniazid
was 13.9 mg/kg (range 12.5-16.1 mg/kg). For
patients in the PH series, the mean daily dosage
of isoniazid at the start of chemotherapy was
4.4 mg/kg body-weight (range 3.7-6.3 mg/kg) and
that of PAS 0.22 g/kg (range 0.18-0.32 g/kg).
Both chemotherapeutic regimens were pre-
scribed for a period of 12 months in the first
instance.
ALLOCATION OF CHEMOTHERAPY
On the basis of the postero-anterior radiograph
and the tomographic series, each patient was clas-
sified into one of the following three categories
by the Centre’s medical staff :
(1) patients with no definite cavitation ;
(2) patients with cavitation, the diameter of the
largest cavity not exceeding 3 cm ; and
(3) patients with cavitation, the diameter of the
largest cavity exceeding 3 cm.
The allocation of treatment was done by the
statistics department from three separate series
of sealed envelopes (one for each of the above
three groups), based on random sampling num-
bers. Nobody had prior knowledge of the chemo-
therapy which any individual patient would
receive.
The first allocation was made on 21 June 1961
and the last on 10 January 1962, by which date
165 patients had been allocated to treatment, 83 to
the SHTW series and 82 to the PH series.
GENERAL MANAGEMENT
All patients were treated on a domiciliary basis.
The SHTW patients were asked to attend the
Centre twice weekly to receive a dose of isoniazid
(under the direct supervision of the clinic staff)
followed by an injection of streptomycin. The PH
patients were instructed to attend the Centre once
a week for a supply of cachets which were to be
taken at home. If any patient failed to attend
on the appointed day, a home visit was paid by
the health visitor the next day as a reminder;
the management of patients who failed to attend
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despite the reminder was decided by the Centre’s
medical staff.
ASSESSMENTS OF PROGRESS
In other respects the management of the
patients followed the same lines as in previous
investigations at the Centre (Tuberculosis Chemo-
therapy Centre, 1960, 1963a, 1963b). In brief,
two visits were usually paid by the health visitors
to all patients every month at approximately fort-
nightly intervals ; at one visit (an unannounced
one in the middle of the month) the stock of
cachets was counted and a specimen of urine was
collected from the PH patients, but no routine pro-
cedure was undertaken in the case of the SHTW
patients. The other visit (at the end of each
month) was to deliver a sputum specimen bottle.
Assessments made at monthly intervals after
the start of chemotherapy included (a) the weight.
(b) a postero-anterior chest radiograph, (c) the
examination of two collection and one supervised
spot specimen of sputum by smear and culture.
and (d) tests of sensitivity to the allocated drugs
on one positive culture.
URINE TESTING FOR ISONIAZID OR PAS
Patients who were initially too ill to attend
the Centre had their chemotherapy administered
at home (SHTW series) or had a stock of cachets
delivered to them at home once a week (PH
series). As soon as they had improved sufficiently,
usually after one or two months, they were
changed to the ordinary routine of clinic and
home visits. The large majority of patients were
ambulant much of the time.
In order to check the self-administration of
medicine in the PH patients, a urine specimen was
obtained at each weekly visit to the Centre and at
the unannounced visit to the home each month
and tested for PAS by the ferric chloride test
(Simpson, 1956). In the early stages of the study,
a single specimen of urine was collected from
each of about a third of the SHTW patients
approximately 24 hours after the supervised
administration of their drugs. This was tested by
the combined naphthoquinone-mercuric chloride
test (Gangadharam et al., 1958).
III. BACTERIOLOGICAL AND ASSAY PROCEDURES
EXAMINATION OF SPUTUM SPECIMENS, AND
SENSITIVITY TESTS
The methods used for examining sputum speci-
mens and for performing tests of sensitivity to
isoniazid, streptomycin and PAS are similar to
those described elsewhere (Tuberculosis Chemo-
therapy Centre, 1959). In brief, sputum smears
were examined by fluorescence microscopy and
were graded as 3-plus, 2-plus, 1-plus or negative.
Sputum specimens, after treatment with 4%
NaOH for 20 minutes, were cultured on Löwen-
stein-Jensen medium which did not contain potato
starch (Jensen, 1955). The cultures were examined
weekly for between eight and nine weeks and
reported as negative if no growth was present
by that time. Sensitivity tests were set up on
Löwenstein-Jensen medium slopes containing the
concentrations of drug set out below as well as
on a drug-free slope as a control. The standard
sensitive strain, H37Rv, was also set up with each
batch of tests. Sensitivity tests for PAS were set
up using a 1: 10 dilution of the standard suspen-
sion as recommended by Selkon et al. (1960). The
tests were read after four weeks’ incubation at
37°C. The drug concentrations used were as
follows:
Drug concentration in mg/ml
Drug Test strain H37Rv
Isoniazid 0.2, 1, 5, 50 0.025, 0.05, 0.1, 0.2, 1
Streptomycin      4, 8, 16, 32, 64 1, 2, 4, 8
Sodium PAS
dihydrate 0.5, 1, 2, 4, 8, 16 0.125, 0.25, 0.5, 1, 2
DEFINITIONS OF BACTERIAL DRUG RESISTANCE
In the following definitions of resistance,.
“ growth ” has been defined as 20 colonies or
more :
Isoniazid
Pretreatment tests. Resistance was defined as:
(a) growth on 1 µg/ml on one culture irrespec-
tive of the result on the other culture;
(b) growth on 0.2 µg/ml but not on 1 µg/ml
followed by growth on 0.2 µg/ml in a repeat test
on the same culture, irrespective of the result on
the other culture ; or
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(c) growth on 0.2 µg/ml but not on 1 µg/ml on
both cultures, irrespective of the results of repeat
tests.
Tests during treatment. Resistance was defined
as growth on 0.2 µg/ml or a higher concentration.
Streptomycin
Pretreatment tests. Resistance was defined as:
(a) a resistance ratio (RR) of 8 or more on one
culture irrespective of the result on the other
culture ;
(b) an RR of 4 followed by an RR of 4 or more
in a repeat test on the same culture, irrespective
of the result on the other culture; or
(c) an RR of 4 on both cultures, irrespective of
the results of repeat tests.
Tests during treatment. Resistance was defined
as an RR of 8 or more, or an RR of 4 followed
by an RR of 4 or more in a repeat test on the
same culture.
PAS
Pretreatment tests. Resistance was defined as:
(a) an RR of 8 or more on both cultures ;
(b) an RR of 8 or more on one culture, and an
RR of 4 on the second culture followed by an
RR of 4 or more in a repeat test on the same
culture ; or
(c) an RR of 4 followed by an RR of 4 or
more in a repeat test, on both cultures.
Tests during treatment. Resistance was defined
as an RR of 8 or more, or an RR of 4 followed
by an RR of 4 or more in a repeat test on the
same culture.
SERUM ISONIAZID ASSAYS
The rate of inactivation of isoniazid was deter-
mined for each patient before treatment following
the method described by Gangadharam et al.
(1961a). The results will be reported elsewhere.
TABLE 1
DOSAGE OF DRUGS IN RELATION TO BODY-WEIGHT
Regimen
SHTW
(Twice weekly)
40-49
50-59
60-69
70-79
80-89
90-99
100-109
110-119
120-129
50-59
60-69
70-79
80-89
90-99
100-109
110-119
120-129
Actual amount of drug given
Isoniazid
(mg)
strepto-
mycin
(g)
PAS
(sodium
salt) (g)
300
350
400
450
550
600
650
700
800
150
150
150
175
175
200
200
200
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
–
–
–
–
–
–
–
–
7.50
7.50
7.50
8.75
8.75
10.00
10.00
10.00
Dosage in relation to body-weight
18.7–13.4
15.6–13.0
14.8–12.7
14.2–12.5
15.2–13.5
14.7-13.3
14.4–13.1
14.1–12.9
14.7–13.6
strepto-
mycin
(mg/kg)
PAS
55.8-44.6 –
44.4-37.2 –
37.0-31.7 –
31.6-27.8 –
27.7-24.6 –
24.8-22.2 –
22.1-20.1 –
20.1-18.5 –
18.4-17.0 –
8.7-5.6 – 0.33-0.28
5.8-4.8 – 0.28-0.24
4.7-4.2 – 0.24-0.21
4.8-4.3 – 0.24-0.22
4.3-3.9 – 0.21-0.19
4.4-4.0 – 0.22-0.20
4.0-3.7 – 0.20-0.18
3.7-3.4 – 0.18-0.17
Number of
patients
(on admission)
1 1
13
26
13
9
3
3
6
19
14
16
10
2
1
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IV. THE PATIENTS ADMITTED TO TREATMENT
In all, 165 patients were admitted to treatment, in 28 % of the SHTW patients as compared with
83 to the SHTW and 82 to the PH series.. Of 31 % of the PH patients, and four or more
these, 15 (four SHTW, 11 PH) were subsequently lung zones were involved in 48 % and 52 %,
found to have been excreting organisms resistant respectively.
to isoniazid and/or streptomycin on admission ;
they have been excluded from the main analysis TABLE 2
and are considered. on page 264 et seq. There RADIOGRAPHIC AND BACTERIOLOGICAL CONDITION
remain 150 patients (79 SHTW, 71 PH) in the main ON ADMISSION TO TREATMENT
analysis who, on admission to the study, (a) had SHTW
organisms sensitive to isoniazid and streptomycin, Condition on admission patientsto treatment
(b) had had, so far as is known, no previous
chemotherapy, or, in eight patients (three SHTW,
five PH) up to two weeks’ chemotherapy and (c)
had followed the prescribed regimen for 12
months apart from the variations mentioned on
page 260 et seq., unless chemotherapy was ter-
minated owing to death, tuberculous deterioration,
major toxicity or uncooperativeness.
No. %
PH patients
No. %
Only two of the 150 patients yielded organisms
resistant to PAS on admission. Since both patients
were in the SHTW series, they have not been
excluded from the main analysis.
PRETREATMENT COMPARISON BETWEEN THE TWO
SERIES
Of the 79 SHTW patients 59 % were males as
compared with 69 % of the 71 PH patients. About
half the patients were between the ages of 15 and
34, namely, 49 % of the SHTW and 56 % of the
PH series. The distributions of the general condi-
tion of the patients on admission were very
similar ; thus 13 % of the SHTW patients and
17 % of the PH patients were in good condition,
71 % and 65 %, respectively, in fair condition and
16 % and 18 %, respectively, in poor or very poor
condition. The two series had broadly similar
weight distributions (Table 1).
The extent of cavitation, the total extent of the
Extent of cavitation :
Nil
Slight
Moderate
Extensive
Total extent of disease :
Trivial or slight
Limited
Moderate
Extensive or gross
Number of lung zones
involved in disease :
1, 2 or 3
4, 5 or 6
Bacterial content of sputum : a
Direct smear negative
Direct smear positive:
1-plus (scanty)
2-plus (moderate)
3-plus (heavy)
Total patients 79 loo
4 5 4 6
26 33 26 37
30 38 30 42
19 24 1 1 15
6 8 1 1
16 20 22 31
35 44 26 37
22 28 22 31
41 52 34 48
38 48 37 52
8 10
18 23
41 52
12 15
7 10
13 18
44 62
7 10
71 100
radiographic lesion and the number of lung zones a First or only collection specimen.
involved in disease were assessed, as described
previously (Tuberculosis Chemotherapy Centre,
1960). from a single full-plate radiograph by an
independent assessor (Dr J. Frimodt-Møller), who
was unaware of the treatment series of any
patient. Cavitation was present in 95 % of the
SHTW and 94 % of the PH patients ; it was exten-
sive or moderate in 62 % and 58 % respectively
(Table 2). Gross or extensive disease was present
Considering the bacterial content of the first
or only collection specimen of sputum, 67 % of
the SHTW patients had a 3-plus or 2-plus smear
as compared with 72 % of the PH patients ; only
10 % of patients in each series had a negative
smear.
To summarize, the two series of patients were
similar on admission to treatment.
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CLINICAL
Deaths
Three patients died of pulmonary tuberculosis,
one (SHTW) within 24 hours of admission, one
(PH) in the first week, and one (SHTW) in the
sixth month. The last patient yielded negative cul-
tures at three and four months, had a radiographic
deterioration, presumed to be tuberculous, in the
fifth month, and died in a seriously malnourished
state with very extensive disease ; no culture
results were available at five months. One other
patient (PH), all of whose cultures were negative
from the first month onwards, died suddenly from
a non-tuberculous cause (believed to be pulmonary
embolism) in the eighth month. Permission for
autopsy was refused for all four patients.
Premature termination of the originally prescribed
chemotherapy owing to radiographic deteriora-
tion
If a patient was considered by the Centre’s
medical staff to have a definite radiographic exten-
sion of the disease which had not been present at
one month, a course of penicillin was given for a
minimum of 10 days. If the lesion persisted or
showed a further spread the complete radio-
graphic series was shown to an independent
assessor, Dr K. S. Sanjivi, who was unaware of
the treatment the patient was receiving. He
decided whether or not the extension was suffi-
ciently serious to warrant termination of the pre-
scribed chemotherapy. Two patients (one SHTW,
one PH) had their prescribed chemotherapy
terminated in the twelfth month for this reason.
No patient had treatment terminated for serious
clinical deterioration.
Premature termination of the originally prescribed
chemotherapy owing to toxicity
As in a previous study (Tuberculosis Chemo-
therapy Centre, 1960) patients whose prescribed
chemotherapy was stopped for more than six
weeks on account of toxicity were classified as
having had their chemotherapy terminated for
toxicity; this applied to three patients (all PH),
treatment being terminated in the first, fifth and
ninth month, respectively. However, a decrease
in the dosage of streptomycin because of toxicity
(page 261) or the addition of pyridoxine for the
treatment of isoniazid toxicity (page 262) to the
chemotherapeutic regimen was not regarded as a
termination of chemotherapy due to toxicity.
Premature termination of chemotherapy owing to
uncooperativeness
Eight patients (seven SHTW, one PH) became
uncooperative and stopped treatment, two in the
third, one in the seventh, three (including the PH
patient) in the eighth, one in the ninth and one
in the tenth month.
TABLE 3
CHANGES IN RADIOGRAPHIC APPEARANCES IN THE 12-MONTH PERIOD a
s
a Two separate assessments on standard radiographs.
b Excluding patients who, during the set period, died of a non-tuberculous condition or had their prescribed chemotherapy
terminated on account of toxicity or non-cooperation.
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Presentation of the results for the patients who
died, whose chemotherapy was prematurely
terminated or who became uncooperative
Patients who died of tuberculosis or whose
prescribed chemotherapy was terminated owing
to deterioration of their disease usually remain in
the totals for the whole year. The patient who died
of a non-tuberculous cause has been included up
to the time of death and those whose originally
prescribed chemotherapy was terminated for rea-
sons of toxicity or uncooperativeness have been
included up to the time of termination of treat-
ment.
Weight changes
During the 12-month period, 84 % of 68 SHTW
patients and 91 % of 66 PH patients assessed
gained weight ; the average change in weight was
a gain of 8.9 lb (4.0 kg) and 8.1 lb (3.7 kg), res-
pectively.
Radiographic changes
The radiographic changes were evaluated by an
independent assessor, Dr J. Frimodt-Møller, who
was unaware of the treatment which any patient
had received. The changes were assessed for the
first six months and then for the year ; the find-
ings are presented in Table 3.
During the first six months, 87 % of 77 SHTW
patients as compared with 91 % of 69 PH
patients showed moderate or greater improve-
ment. The proportions of patients who died of
tuberculosis were 3 % and 1 %, respectively. Over
the full 12 months 92 % of 72 SHTW patients and
94 % of 66 PH patients showed moderate or
greater improvement, and 4 % and 3 %, respec-
tively, died of tuberculosis or had their chemo-
therapy terminated on account of deterioration.
Thus, the radiographic progress of the two treat-
ment series was similar.
Changes in cavitation
Table 4 presents the changes in cavitation for
the 12-month period as assessed by the inde-
pendent assessor. Cavitation disappeared in 24 %
of 70 SHTW patients as compared with 21 % of
63 PH patients, and became less in 69 % and
68 %, respectively. The progress of the two series
was also similar when patients with extensive,
moderate or slight initial cavitation were con-
sidered separately.
Five patients (two SHTW, three PH) had no
cavitation on admission ; in one (PH) of them
it appeared at 12 months.
TABLE 4
CHANGES IN CAVITATION IN THE 12-MONTH PERIOD IN PATIENTS WITH CAVITATION
ON ADMISSION TO TREATMENT a
Termination
Tuberculous
death
No. %
1 (6)
0 (0)
a Assessment on standard radiographs on admission to treatment and at 12 months.
b Excluding patients who had their prescribed chemotherapy terminated on account of toxicity or non-cooperation.
c The parentheses indicate percentages based on fewer than 25 observations.
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BACTERIOLOGICAL
Smear and culture results
The smear and culture results of the first (or
only) collection specimen of sputum at each
month are shown in Table 5. At three months,
the culture was negative in 82 % of 76 SHTW
and 72 % of 69 PH patients ; at six months the
proportions were 89 % and 88 %, at nine months
93 % and 89 %, and at 12 months 94 % and
89 %, respectively.
Multiple specimens were examined for each
patient monthly, the average number of test results
per month ranging from 2.6 to 2.9 for patients
in both series. The percentage of patients each
month with at least one positive culture is shown
for the two series in the figure overleaf. In
both series, there was a rapid decline in the
proportion of patients with at least one positive
TABLE 5
PRESENCE OF TUBERCLE BACILLI IN SINGLE COLLECTION SPECIMENS OF SPUTUM
Treatment Total
chemotherapy series patients 
a
Smear Smear
positive negative
SHTW 79 71 7
0
PH 71 63 6
SHTW 78 1 35 23
1
PH 70 24 30
SHTW 75 15 21
2
PH 69 1 13 16
SHTW 76 5 8
3
PH 69 4 14
SHTW 72 1 3 9
4
PH 68 5 5
SHTW 74 1 2 4
5
PH 64 1 6 2
SHTW 75 2 3 3
6
PH 67 3 4
SHTW 72 2 2 1
9
PH 65 2 4
SHTW 72 3 1 0
12
PH 66 2 3 2
a Patients who died of a non-tuberculous condition or had their prescribed chemotherapy terminated on account of toxicity:
or non-cooperation are excluded thereafter.
b Even if the smear was positive.
Termination of
prescribed
chemotherapy
on account of
deterioration,
or tuberculous
death
0
0
Culture
negative b
No. %
1 1
2 3
19 24
15 21
38 51
39 57
62 82
50 72
59 82
57 84
67 91
55 86
67 89
59 88
67 93
58 89
68 94
59 89
Culture positive
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culture, and, in the second six months, this pro-
portion was usually slightly smaller in the SHTW
series.
PERCENTAGE OF PATIENTS EACH MONTH WITH
AT LEAST ONE POSITIVE CULTURE FROM MULTIPLE
BACTERIOLOGICAL SPECIMENS
Sensitivity tests
Isoniazid. The results of isoniazid sensitivity
tests are set out in Table 6. (These were not avail-
able for 10 (2.6 %) of 383 cultures.) At three
months, a resistant culture was obtained from
three (4 %) of 76 SHTW patients and from two
(3 %) of 69 PH patients. The corresponding pro-
portions at six and 12 months were 5 % and 10 %,
and 1 % and 6 %, respectively. Considering the
proportions of positive cultures that were resistant,
three of 20 cultures at three months were resistant
in the SHTW series as compared with two of 20
in the PH series ; at six months the proportions
were four of nine and seven of eight cultures,
respectively. In the second six months of treat-
ment, 12 (80 %) of 1.5 cultures in the SHTW
series and 41 (84 %) of 49 cultures in the PH
series were resistant.
Streptomycin. At one month, two (3 %) of 78
SHTW patients yielded a streptomycin-resistant
culture ; this proportion remained practically the
same for the rest of the year. In the second six
months of treatment, 11 of 15 positive cultures
tested were resistant, all with resistance ratios of
more than eight.
Emergence of resistance in the SHTW patients.
Resistance to isoniazid or streptomycin (or both)
emerged during treatment in 10 of the 78 SHTW
patients. Sputum conversion (that is, three con-
secutive months of culture negativity) occurred
after the emergence of resistance in five patients ;
in four of these, only a single culture was resistant
(two to isoniazid, one to streptomycin and one to
both) and the fifth patient had two cultures resistant
to isoniazid. A further three patients each yielded
an isolated positive culture which was resistant (two
to isoniazid and one to both isoniazid and strepto-
mycin) after sputum conversion. All these eight
patients were regarded as having had a favour-
able response to treatment at 12 months (see
page 258 et seq). Of the remaining two patients,
both of whom were classified as having had
an unfavourable response to treatment, one
had isoniazid-resistant cultures at each month
from two to 12 months, the cultures at three, five,
seven and subsequent months being streptomycin-
resistant also. The other patient had isoniazid-
resistant cultures at each month from two to 11
months when treatment was terminated owing to
radiographic deterioration. The cultures in this
patient were streptomycin-resistant at one, three,
and five to 11 months. In both patients the
majority of the cultures were fairly highly resistant
to isoniazid (growth on 5 µg/ml) and to strepto-
mycin (RR of more than 8).
Of the remaining 68 patients, who never yielded
a resistant culture during treatment, none re-
mained consistently bacteriologically positive with
isoniazid-sensitive and/or streptomycin-sensitive
organisms throughout the 12 months.
Emergence of resistance in the PH patients.
Resistance to isoniazid emerged during treatment
in 14 of 69 PH patients. In three, sputum conver-
sion occurred after the emergence of a single
isoniazid-resistant culture. A further four patients
produced one or more resistant cultures after
sputum conversion. One of these produced an
isoniazid-resistant culture at 11 months but an
isoniazid-sensitive culture at 12 months, and has
been classified as having had an unfavourable
response to treatment. Of the other three, one
produced resistant cultures at five and eight
months, another at seven, eight, nine and 10
months and the third at 10, 11 and 12 months ;
according to definition, only the last patient has
been regarded as having had an unfavourable
Months
after start
of chemo-
therapy
1
2
3
4
5
6
7
8
9
10
1 1
12
T reatment Total Total
series patients 
b
(A) resultsavailable
(B)
SHTW 78 67
PH 69 60
SHTW 76 45
PH 69 35
SHTW 76 20
PH 69 20
SHTW 73 14
PH 69 14
SHTW 74 8
PH 68 9
SHTW 75 9
PH 67 6
- -
SHTW 74 3
PH 68 12
SHTW 72 2
PH 65 9
SHTW 70 3
PH 64 6
- -
SHTW 67 2
PH 65 9
SHTW 68 4
PH 62 7
- -
SHTW 69 e 1
PH 64 e 6
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TABLE 6
RESULTS OF ISONIAZID-SENSITIVITY TESTS IN THE 12-MONTH PERIODa
1 2 3 (67)
2 6 9 (100)
1 2 3 (100)
3 6 12 (89)
2 3 4 (75)
4 7 11 (100)
1 i 1 1 (100)
1 4 6 (67)
a All patients had strains sensitive to isoniazid before treatment.
b All patients who died are excluded after their death and patients who had their prescribed chemotherapy terminated on
account of toxicity or non-cooperation are excluded thereafter.
c The parentheses indicate percentages based on fewer than 25 observations.
d No test result on 50 µg/ml for one (or only) patient.
e Excluding 1 patient who deteriorated and had his prescribed chemotherapy terminated. (The culture at 11 months yielded
growth on 50 µg/ml.)
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response to treatment. A further seven patients
had bacteriologically active disease throughout
with resistant cultures first emerging at one, three,
four, four, four, four and five months, respec-
tively. (All the cultures isolated during treatment
from four of these patients were sensitive to PAS.)
Of the remaining 55 patients, who never
yielded an isoniazid-resistant culture during treat-
ment, only one was persistently bacteriologically
positive with isoniazid-sensitive organisms through-
out the year ; this patient was irregular in taking
his drugs, had treatment changed to twice-weekly
streptomycin plus isoniazid in the ninth month on
account of toxicity to PAS, continued to excrete
isoniazid-sensitive organisms for the rest of the
year, and has been regarded in this section as
having had an unfavourable response to treat-
ment.
Resistance to PAS emerged during treatment
in 13 patients. Eight of these yielded a PAS-
resistant culture on one occasion only and sputum
conversion occurred thereafter in five ; the other
three (including the one who persistently pro-
duced isoniazid-sensitive cultures) produced the
resistant culture at seven, 10 and 12 months,
respectively, and had an unfavourable response.
A further four patients yielded two resistant cul-
tures each; in three, this was followed by five or
more months of culture negativity and the fourth,
who produced resistant cultures at six and nine
months, had bacteriologically active disease at 12
months. Finally, one patient produced resistant
cultures at seven, nine and 10 months and had
active disease throughout. (Of the five patients
with PAS-resistant strains who had an unfavour-
able response to treatment, isoniazid resistance
preceded PAS resistance in four; the fifth was
isoniazid-sensitive throughout.)
In summary, isoniazid resistance emerged in
nine of the 78 SHTW patients and in 14 of the
69 PH patients. However, in only three SHTW
and 10 PH patients were two or more resistant
cultures produced ; two of the former and eight of
the latter had an unfavourable response to treat-
ment. Resistance to streptomycin was observed in
five SHTW patients ; two of these yielded resistant
cultures on more than one occasion and both had
an unfavourable response. PAS resistance emerged
in 13 PH patients and was associated with an
unfavourable response in five.
Both patients in the SHTW series who remained
consistently bacteriologically positive yielded orga-
nisms with fairly high degrees of resistance
to isoniazid and streptomycin. Isoniazid resistance
emerged in seven of eight patients who remained
consistently bacteriologically positive
series, and PAS resistance in four.
in the PH
RESPONSE TO TREATMENT DURING THE 12 MONTHS
Table 7 presents a classification of all the
patients at 12 months, based primarily on the
bacteriological response to treatment. In all, 92 %
of 72 SHTW patients as compared with 80 %
of 66 PH patients had bacteriologically quiescent
disease and 3 % and 5 %, respectively, had disease
of bacteriologically doubtful status, which is also
regarded as a favourable response to treatment
(Velu et al., 1960, 1961a). The proportions of
patients with an unfavourable response to treat-
ment, defined as death from tuberculosis, bacterio-
logically relapsed disease or bacteriologically active
disease at 12 months including termination of
prescribed chemotherapy owing to deterioration,
were 6% for the SHTW and 15 % for the PH
series ; this difference is not statistically significant
(P > 0.1).
Twelve patients (seven SHTW, five PH) are
not included in the above totals, eight (seven
SHTW, one PH) because they became uncoopera-
tive and stopped treatment, three (all PH) because
they had their prescribed chemotherapy termin-
ated on account of toxicity and one (PH) because
he died from a non-tuberculous cause.
Four of the seven uncooperative SHTW patients
stopped treatment in the third, eighth, ninth and
tenth months (after one, six, three and four con-
secutive months, respectively, of culture negativity).
Nevertheless, one had cultures examined at 10, 11
and 12 months, a second at 11 and 12 months,
and the other two at 12 months. All the
cultures were negative and consequently the four
patients were regarded as having had a favour-
able response. Two patients had an unfavourable
response. One of these stopped treatment in the
seventh month after six consecutive months of
smear and culture negativity and produced two
positive cultures (isoniazid-resistant, streptomycin-
sensitive) at 12 months. The other, who had stop-
ped treatment in the third month after one month
of culture negativity, was examined at seven
months when he produced one positive culture
(sensitive to both isoniazid and streptomycin) ; he
subsequently died of pulmonary tuberculosis in the
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TABLE 7
CLASSIFICATION OF ALL PATIENTS AT THE END OF 12 MONTHS ACCORDING TO THEIR RESPONSE TO TREATMENT
SHTW
Treatment series
PH             
No. %No. %
Classification at the end of 12 months
Patients with bacteriologically quiescent disease :
that is, patients whose cultures were all negative for at least the
last three monthly examinations-i.e., at 10, 11 and 12 months
First month of
persisting culture
negativity
1
2
3
4
5
6
7
8
9
10
9 6
16 19
17 7
7 9
6 6
1 1
7 1
2 3
0 1
1 0
Total 66 92 53 80
Patients with disease of bacteriologically doubtful status :
that is, patients whose cultures were all negative at three or more consecutive monthly
examinations but who produced a single positive culture at one of the lastthree monthly
examinations-i.e., at 10, 11 or 12 months 2 3 3 5
68 94 56 85Total patients with favourable response
Patients with bacteriologically relapsed disease :
that is, patients whose cultures were all negative at three or more consecutive monthly
examinations, but who produced two or more positive cultures in the last three monthly
examinations-i.e., at 10, 11 and 12 months 0 0 3 5
Patients with bacteriologically active disease :
that is, (a) patients whose cultures were never all negative at three consecutive monthly
examinations, or
(b) patients who deteriorated and had their prescribed chemotherapy terminated
1 1
1 1
5 8
1 2
1 2
10 15
2 3Tuberculous deaths
Total patients with unfavourable response 4 6
Total 72 100 66 100
7  – 1  –
3  –
1  –
Patients who became uncooperative and stopped treatment
Patients who had their prescribed chemotherapy terminated on account of toxicity
Non-tuberculous death
0  –
0  –
All patients 79               – 71                            –
260 TUBERCULOSIS CHEMOTHERAPY CENTRE, MADRAS
eleventh month. The seventh patient stopped treat- therapeutic efficacy of the two regimens, the pro-
ment in the eighth month after five consecutive portions with favourable response become 92 %
months of culture negativity ; she refused to attend of 78 SHTW patients and 84 % of 67 PH patients
the Centre subsequently for examination and it was (P ~ 0.2).
therefore not possible to assess the status of her Three patients (all PH) had their originally pre-
disease at 12 months. The uncooperative PH scribed chemotherapy terminated on account of
patient, who had been persistently sputum posi- toxicity, one in the first month, one (culture nega-
tive with isoniazid-resistant organisms, stopped tive at four months) in the fifth month and one,
treatment in the eighth month ; at 10 and 11 who had been persistently sputum positive on
months, he produced isoniazid-resistant strains and smear and culture with isoniazid-sensitive strains,
has been regarded as having had an unfavourable in the ninth month. One patient (PH), who had
response. If the seven uncooperative patients (six consistently negative cultures from the first to
SHTW, one PH) whose response could be assessed the seventh month, died from a non-tuberculous
are taken into consideration in assessing the cause in the eighth month.
VI. RESPONSE TO TREATMENT RELATED TO VARIOUS FACTORS
ON ADMISSION TO TREATMENT
Table 8 relates factors in the pretreatment con- zones involved ; the corresponding figures for the
dition to the frequency of unfavourable response PH patients were 29 % of 34 and none of 32.
to treatment (defined on page 258). Of 44 With regard to the bacterial content of the
SHTW patients with extensive or moderate cavi- sputum, 6 % of 48 SHTW patients with 3-plus or
tation 9 % had an unfavourable response as com- 2-plus smears showed an unfavourable response
pared with none of 28 with slight or no cavita- as compared with 4% of 24 with 1-plus or nega-
tion ; the corresponding proportions fo r  PH tive smears, and among PH patients 15 % of 47
patients were 24 % of 38 and 4 % of 28. Of 21 as compared with 16 % of 19, respectively.
SHTW patients who had gross or extensive In summary, there was some evidence from both
disease, 10 % showed an unfavourable response series that an unfavourable response to treatment
as compared with 4 % of 51 with less extensive occurred more frequently in patients with larger
disease ; the corresponding proportions for PH radiographic lesions than in patients with relatively
patients were 40 % of 20 and 4 % of 46. Of 36 small lesions. However, the differences were signifi-
SHTW patients with four or more lung zones cant only in the PH series in respect of the total
involved in disease, 6 % had an unfavourable extent of disease and the number of lung zones
response as compared with 6 % of 36 with fewer involved in disease (P ~ 0.001).
VII. TOXICITY AND OTHER COMPLICATIONS
DRUG TOXICITY
Of the 150 patients in the main analysis, two
(one SHTW, one PH) who died within a week of
starting treatment have been excluded from the
analysis of drug toxicity as they were observed
for so short a period. There remain 78 SHTW
and 70 PH patients.
Streptomycin
Complaints of giddiness were used to assess the
incidence of possible streptomycin oto-toxicity.
Only spontaneous complaints were recorded ; in
order to prevent the patients and nursing staff
from becoming unduly conscious about the
occurrence of symptoms and signs of toxicity,
it was the policy not to interrogate the patients to
elicit symptoms. In the present study, giddiness
occurred usually half an hour to two hours after
the injection and was normally short lasting,
rarely persisting overnight.
Spontaneous complaints of giddiness were re-
corded at some time during the year for 27
(35 %) of 78 SHTW patients–for 17 on one
occasion, and for 10 on more than one occasion
(namely, twice in five, three times in three, four
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TABLE 8
RESPONSE TO TREATMENT RELATED TO VARIOUS FACTORS ON ADMISSION
TO TREATMENT a
Condition on admission to treatment
Extent of cavitation :
Extensive
Moderate
Slight
Nil
Total extent of disease :
Gross or extensive
Moderate or limited
Slight or trivial
Number of long zones :
6, 5 or 4
3, 2 or 1
Bacterial content of sputum : c
3-plus
2-plus
1-plus
Negative
Total patients
SHTW series
Total
patients
18
26
26
2
21
46
5
36
36
10
38
17
7
72
Unfavourable Total
response b patients
1
3
0
0
2
2
0
2
2
1
2
1
0
4
9
29
25
3
20
45
1
34
32
5
42
13
6
66
PH series
Unfavourable
response b
10
0
a Excluding patients who died of a non-tuberculous condition or had their prescribed chemo-
therapy terminated on account of toxicity or non-cooperation.
b For definition, see text (page 258).
c Direct smear grade on first or only collection specimen.
times in one and five times in one). Of the 10
patients who complained more than once, five had
their dosage of streptomycin reduced to approxi-
mately 15 mg/kg body-weight, three of them for
the rest of the year and two for only two and
four weeks, respectively ; giddiness was complained
of subsequently by three on only one occasion
and by one on two occasions. Of the 17 patients
who complained on a single occasion, five did
so in the first three months, one in the second
three months and 11 in the last six months. Of
the 10 patients who complained on more than
one occasion, the numbers who complained for
the first time in the corresponding periods were
four, four and two, respectively.
It is uncertain how often the complaints of giddi-
ness were due to streptomycin toxicity as giddi-
ness was also noted in eight (11 %) of the 70
PH patients even though it was less likely to
have been recorded in them because it is not
a recognized toxic manifestation of therapy with
PAS plus isoniazid.
Hypersensitivity reactions to streptomycin were
not encountered.
Isoniazid
Two (3 %) of the 78 SHTW patients and none
of the 70 PH patients developed toxic reactions
attributed to isoniazid. One patient had convul-
sions a few hours after the administration of
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chemotherapy on two occasions (in the first and
sixth weeks) ; they did not recur after pyridoxine,
in a dosage of 6 mg twice weekly, was added to
the patient’s chemotherapy. The other patient deve-
loped peripheral neuropathy in the second month ;
pyridoxine in a dosage of 6 mg twice weekly was
added to the patient’s chemotherapy with subse-
quent improvement. In both, the SHTW regimen
was continued.
PAS
Three (4 %) of the 70 patients developed cuta-
neous hypersensitivity reactions to PAS, one in the
first and two in the second month of treatment.
Treatment had to be terminated in these patients
in the first, fifth and ninth month, respectively, as
the reactions could not be controlled in spite
of attempts at desensitization under cover of
corticosteroids.
As in earlier studies (Tuberculosis Chemo-
therapy Centre, 1959, 1960), gastrointestinal side-
effects were unimportant and did not make it
necessary to reduce the dosage of the drug in any
patient.
In summary, giddiness was a common com-
plaint and occurred in 35 % of the patients in
the SHTW series and 11 % of the patients in the
PH series ; however, a reduction of streptomycin
dosage became necessary only in five SHTW
patients. Isoniazid toxicity occurred in two SHTW
patients and was treated successfully with a small
dosage of pyridoxine. PAS hypersensitivity led to
termination of chemotherapy in three PH patients.
UNCOOPERATIVE PATIENTS
Seven SHTW patients became uncooperative
and stopped treatment, two in the third, one in
the seventh, two in the eighth, one in the ninth
and one in the tenth month. One, who had severe
asthma, stopped because he was disappointed that
his treatment was not controlling his asthmatic
attacks; a second, who was an alcoholic, spent a
term in prison and refused to attend the Centre
after his release. Four others (including one
alcoholic) complained of giddiness (on four, two,
one and one occasions), the dosage of streptomy-
cin being reduced in one. In these four patients
streptomycin toxicity may have played a part in
the patient’s stopping treatment. The seventh
patient stopped treatment for no apparent reason.
One PH patient, who was an alcoholic, became
uncooperative and stopped treatment in the eighth
month.
HOSPITAL AND SANATORIUM ADMISSIONS
Two patients were admitted to sanatorium on
account of pulmonary tuberculosis. One (SHTW)
died of tuberculosis (in the sixth month) the day
after admission and the other (PH) was an in-
patient for 43 weeks for a pyopneumothorax with
a bronchopleural fistula. In-patient treatment for
non-tuberculous conditions was given to four
SHTW patients for three, five, five and 27 weeks,
and five PH patients for one, two, two, five and
eight weeks.
VIII. REGULARITY OF ADMINISTRATION OF CHEMOTHERAPY
MISSED OR LATE ATTENDANCES IN THE SHTW SERIES istration of chemotherapy. Attendances which
were early by one or more days did not cause
As stated earlier (page 249), it was a rule any extra work for the Centre’s staff but attend-
that patients should attend the Centre for their ances late by one or more days or missed
treatment. However, chemotherapy was given in altogether entailed one, two or three additional
the home on 148 occasions to 13 patients who home visits.
were too ill to attend the Centre. To discourage
the rest of the patients from defaulting deliber-
An analysis was undertaken to study the regu-
ately in order to obtain treatment at home, chemo-
larity with which the patients attended the Centre
for treatment. In brief, 6335 (87.0 %) of the
therapy was very seldom given to them in the
home-namely, to three patients on a total of
7279 scheduled attendances were made on the ap-
pointed day or earlier, on 4.7 % of occasions the
four occasions. patients attended one to three days late, and
During the year each patient was scheduled to 8.3 % of the attendances were missed altogether.
attend on 104 occasions for the supervised admin- The detailed findings are presented in Table 9.
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TABLE 9
REGULARITY OF ADMINISTRATION OF CHEMOTHERAPY
IN SHTW PATIENTS AS ASSESSED BY MISSED
OR LATE ATTENDANCES FOR TREATMENT
Percentage of
attendances
missed a
0
1-4
5-9
10-14
15-24
25 or more
Total
Patients b
No. %
7 10
25 35
19 27
6 8
9 13
5 7
71 100
Of these, number
of patients who
attended late
57
a Excluding periods in hospital or sanatorium. For patients
who died of tuberculosis or had their chemotherapy terminated
on account of deterioration, the percentage is based on atten-
dances up to (but not including the month of death or termination.
b  Excluding one patient who died within 24 hours of
admission and seven patients who had their prescribed chemo-
therapy terminated on account of non-cooperation.
It will be seen that seven (10 %) patients received
all the prescribed chemotherapy during the year,
44 (62 %) patients failed to receive chemotherapy
on 1-9 % of occasions, 15 (21 %) on 10-24 % of
occasions and five (7 %) on 25 % or more
of occasions.
Patients who were frequently non-attenders also
frequently attended late by one day or more;
thus, of seven patients who never missed an
attendance, only two attended late on one or more
occasions during the year, as compared with 18
of 25 who missed 1-4 % of attendances, 17 of 19
who missed 5-9 % and all of 20 who missed 10 %
or more.
An analysis (not tabulated here) was under-
taken to study whether there were any differences
in the regularity of attendance during the course
of the year. In the first three months of treat-
ment, 46 % of 71 patients attended on the
appointed day or earlier on all occasions, as com-
pared with 23 % of 69 in the second three months,
28 % of 69 in the third, and 22 % of 68 in the
last three months of the year of treatment. The
proportions of patients who attended after the
appointed day or did not attend at all on 25 %
or more of the occasions during each three-
monthly period were 4 %, 13 %, 19 % and 31 %,
respectively.Thus there was an association between
irregularity and length of treatment.
Seven patients, who became so uncooperative
that they discharged themselves from treatment
during the year, have been excluded from the
above analyses. Of these, six missed 15 % or more
of their scheduled attendances as compared with
14 of the 71 patients who remained under treat-
ment, a difference which attains statistical signi-
ficance (P<0.01). Thus, the particularly unco-
operative patients were more irregular even before
they stopped treatment.
SUPERVISION OF THE ADMINISTRATION OF ISONIAZID
IN THE SHTW SERIES
Since it is known that pills may be expector-
ated even when given under supervision (Gilroy,
1952), it was desirable to obtain confirmation
that isoniazid had been swallowed. For this pur-
pose urine specimens obtained at home visits
were tested for isoniazid (Gangadharam et al.,
1958), using a test for which a negative result
indicates, in a large proportion of patients, that
no drug has been taken for at least 24 hours
previously (Tuberculosis Chemotherapy Centre,
1963a). Specimens of urine collected from 28
SHTW patients 24 hours after a dose all gave
positive results ; 15 of 16 further specimens col-
lected at 24 hours from nine of these patients
were also positive.
URINE TEST RESULTS IN THE PH SERIES
The regularity of self-administration of chemo-
therapy in the PH series was studied by consider-
ing the results of tests for PAS on urine speci-
mens obtained at the weekly routine visits to the
Centre. A negative result means that no PAS has
been taken for 14 hours, so that the equivalent
of at least a day’s supply of medicine has, in all
probability, been missed (Tuberculosis Chemo-
therapy Centre, 1960). It is likely that the degree
of irregularity has been underestimated by using
the results of clinic urine specimens, as the fact
that a visit was due may have acted as a reminder
to take the drug ; also, many patients knew that
the specimens were tested for drug. (The results of
tests on urine specimens at surprise visits to the
home, though useful for supervision, have not
been presented because certain factors could have
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TABLE 10
REGULARITY OF SELF-ADMINISTRATION OF
CHEMOTHERAPY IN PH PATIENTS AS
ASSESSED BY TESTS ON CLINIC URINE SPECIMENS
Percentage of urine test results
which were negative a
Patients b
No. %
0 19 28
1-4 15 22
5-9 6 9
10-14 7 10
15-24 8 12
25-34 5 7
35 or more 8 12
68 100
a Excluding periods in hospital or sanatorium. For patients
who died or had their chemotherapy terminated on account
of deterioration or toxicity, the percentage is based on the test
results up to (but not including) ‘the month of death or
termination.
b Excluding one patient who had his prescribed chemo-
therapy terminated on account of toxicity and one patient who
died of tuberculosis. both in the first month. and one patient
who had his chemotherapy terminated on account of non-
cooperation.
introduced bias into the assessment of regularity
of drug-taking from such visits : first, the seriously
ill patients were more likely to be found at home
and, secondly, more frequent visits were often
requested by the doctors for patients whose test
results were negative.)
The average number of clinic urine tests per
month per patient was 3.8. From Table 10 it will
be seen that 28 % of 68 patients had no negative
urine test results during the year, 31 % had
1-9 % negative results, 22 % had 10-24 %, and
19 % had 25 % or more negative results. The
proportions of patients who had no negative test
results during the four three-monthly periods
were 54 % of 68, 66 % of 67, 60 % of 65 and
47 % of 64, respectively, the corresponding propor-
tions of those who had negative test results on
25 % or more occasions being 16 %, 19 %, 18 %
and 23 %, respectively. Thus there was no evidence
of an association between duration of treatment
and irregularity. The PH patient who became
uncooperative and discontinued treatment had
negative results for 15 % of specimens.
RESPONSE TO TREATMENT IN RELATION TO THE
REGULARITY OF ADMINISTRATION OF CHEMOTHERAPY
SHTW series
Of the three SHTW patients who survived more
than one month and had an unfavourable
response, one, who had his chemotherapy termina-
ted owing to deterioration in the eleventh month,
attended on all of 96 occasions ; the second, who
had active disease at one year, missed eight of
104 attendances, and the third, who died in the
fifth month, missed one of 36 attendances. Of
the 68 patients who had a favourable response,
seven (10 %) missed 20 % or more of their
scheduled attendances.
PH series
Analyses (not presented here) showed that
there was no association between irregularity in
self-administration of chemotherapy, either in the
first three months or over the whole year, and
response to treatment ; thus three (16 %) of 19
patients who had no negative urine test results
during the year had an unfavourable response, as
compared with two (10 %) of 21 with 1-9 % nega-
tive urine test results, and four (16 %) of 25
patients with 10 % or more negative urine test
results.
IX. PATIENTS WITH RESISTANT ORGANISMS ON ADMISSION TO STUDY
Fifteen patients (four SHTW, 11 PH), all of treatment, as their relations with the Centre’s
whom received the allocated regimen, were ex- staff became more firmly established, to discover
eluded from the main analysis because they had whether they had concealed having received
resistant organisms on admission to the study previous chemotherapy ; four (three isoniazid-
(page 252), seven to isoniazid, five to strepto- resistant, one resistant to both drugs) admitted to
mycin and three to both drugs. These patients previous chemotherapy. It was presumed that
were interrogated again during the course of the remaining 11 patients (four isoniazid-resistant,
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five streptomycin-resistant and two isoniazid- and
streptomycin-resistant) had been infected with
resistant organisms.
All four patients (one SHTW, three PH) with
acquired isoniazid resistance had an unfavourable
response to treatment. The detailed results of
sensitivity tests to isoniazid and streptomycin on
two pre-study cultures are set out for these patients
in the upper part of Table 11.
Of the six patients (two SHTW, four PH)
with primary isoniazid resistance, two (one
SHTW, one PH) had a favourable response to
treatment and the remaining four had an un-
favourable response. There was one SHTW
patient with primary streptomycin-resistant but
isoniazid-sensitive strains, and he had an un-
favourable response to treatment. The detailed
results of pretreatment sensitivity tests are set out
for these seven patients in the lower part of
Table 11.
According to the definitions given on page
251, only two patients (both SHTW) yielded
organisms resistant to PAS on admission to
treatment. These patients were included in the
main analysis. A less stringent definition of resist-
ance, similar to that adopted in other studies
(East African/British Medical Research Council,
1959, 1960a, 1960b, 1963), is as follows: an RR
of 8 or more on one pretreatment culture, or an
RR of 4 followed by an RR of 4 or more in a
repeat test on the same culture, or an RR of 4 on
both cultures irrespective of the results of repeat
tests. Using this definition, the organisms from
17 patients (13 SHTW, four PH) would be con-
sidered resistant. (Of these, only one patient
(SHTW), whose organisms were also resistant to
isoniazid on admission, has been excluded from
the main analysis.) For reasons to be reported
elsewhere, this definition probably overestimates
the prevalence of PAS resistance. Of the four PH
patients with pretreatment PAS resistance (as
defined above), three had a favourable response
and the fourth had bacteriologically active disease
at 12 months.
TABLE 11
RESPONSE TO TREATMENT RELATED TO SENSITIVITY TEST RESULTS ON ADMISSION IN PATIENTS WITH ACQUIRED
OR PRIMARY RESISTANCE TO ISONIAZID AND/OR STREPTOMYCIN
Acquired
resistance
Primary
resistance
Serial
number
lsoniazid
Treatment
cultures
Classification
97 SHTW 50 >50 Resistant
32 PH >50 >50 Resistant
41 PH 50 50 Resistant
163 PH 5 5 Resistant
94 SHTW >50 >50 Resistant
33 SHTW 5 50 Resistant
124 PH 131 1,1 Resistant
141 PH >50 0.05 Resistant
63 PH 1,1 1,1 Resistant
87 PH 50 50 Resistant
113 SHTW 1,0.2 0.05 Sensitive
Sensitivity on admission
Streptomycin
0.5 0.5
2 1
0.5 1
8 4,1
0.5 1
1 0.5
1 0.5
0.5 2
8 8
>8 >8
4,2 4,2
Classification
Sensitive Unfavourable b
Sensitive Unfavourable
Sensitive Unfavourable
Resistant Unfavourable
Sensitive Unfavourable
Sensitive Favourable c
Sensitive Unfavourable
Sensitive Unfavourable
Resistant Unfavourable
Resistant Favourable
Resistant Unfavourable
Response to
treatment
a Minimal inhibitory concentration.
b Tuberculous death or bacteriologically active disease at 12 months including change of chemotherapy for persistent sputum
positivity.
c Bacteriologically quiescent disease at 12 months.
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X. DISCUSSION
In the chemotherapy of pulmonary tuberculosis
it is standard practice to give two or more drugs
in one or more doses daily; in out-patients the
drugs are normally self-administered and irregu-
larity of drug taking, sometimes of a serious
degree, is common. Supervised administration
of the drugs could overcome this disadvantage
but this would be practicable in developing coun-
tries only if treatment could be given inter-
mittently–say, twice a week or less frequently.
Such intermittent chemotherapy might have addi-
tional advantages over daily treatment in being
more economical and probably less toxic (and
therefore more acceptable) to the patients.
Several forms of intermittent chemotherapy in
the treatment of pulmonary tuberculosis have
been reported in the literature. Regimens con-
sisting of one drug (usually isoniazid or PAS)
given daily plus another (usually streptomycin)
given intermittently on two or three days in a
week are no longer regarded as adequate by
most authorities (Medical Research Council, 1955 ;
Crofton, 1960 ; McDermott, 1960 ; Canetti, 1962).
Regimens in which both drugs are given inter-
mittently have been used as continuation treatment
following a period of daily drug therapy ; thus,
intermittent streptomycin plus isoniazid, both
drugs being given together every other day, has
been used with good results after an initial period
of one to three months of daily combined chemo-
therapy by Mackay-Dick (1954, 1959), Hutton et
al. (1956), Todd et al. (1956) and Eade et al.
(1959). There have, in addition, been a few
reports of intermittent chemotherapy from the
start of treatment. Frimodt-Møller et al. (1953)
in a controlled trial compared isoniazid alone
every fourth day with daily isoniazid given as
a quarter of the intermittent dosage, and found
similar radiographic responses in the two series
at 12 weeks. Holmes et al. (1962) treated 29
patients with far advanced disease with a very
large dose of isoniazid alone given once a week
for periods of up to three months, but only two
patients became culture negative. Schaefer (1955)
reported on 15 American-Indian patients treated
with an intramuscular injection of streptomyclidine
isonicotinyl hydrazide-sulfate every three days.
Of nine patients who were culture positive on
admission, three were culture negative at four
months, while at eight months, all of five patients
examined were culture negative. Katz et al. (1954)
and Chambers et al. (1955) reported on a small
group of patients treated with 2 g of streptomycin
plus 500 mg of isoniazid twice weekly. They con-
cluded that the response in these patients was
inferior to earlier findingswith daily isoniazid plus
twice-weekly streptomycin. Tyrrell (1956) gave
newly diagnosed patients 1 g of streptomycin plus
400 mg of isoniazid on the same day, twice
weekly, half being treated in hospital and half
as ambulatory out-patients. At six months sputum
conversion had occurred in 78% of 45 in-patients
and in 80 % of 46 out-patients.
EFFICACY
The present report confirms the conclusions
based on interim findings which were published
in a preliminary communication (Tuberculosis
Chemotherapy Centre, 1963c). Thus, streptomycin
plus high-dosage isoniazid, both drugs being given
together twice a week under supervision (SHTW
regimen), has proved to be successful in the
treatment of newly-diagnosed, far advanced, bac-
teriologically positive pulmonary tuberculosis, and
at least as effective as a standard oral two-drug
regimen of PAS plus isoniazid prescribed for
self-administration daily (PH regimen). Thus, at
one year, 94 % of 72 SHTW patients compared
with 85 % of 66 PH patients had bacteriologically
quiescent disease (including disease of bacterio-
logically doubtful status) and 92 % and 94 %,
respectively, showed moderate or greater radio-
graphic improvement.
It is of interest to compare the findings in this
study with those obtained by the Medical
Research Council (1955). In the latter, strepto-
mycin was given intermittently in a dose of 1 g
twice a week (about 18 mg/kg body-weight) and iso-
niazid daily in a dosage of 200 mg. Thus, the total
weekly dosage of isoniazid and streptomycin was
approximately the same in both studies although
the individual dose in the present study was much
higher in the case of isoniazid (650 mg) and,
because of the light weight of the Indian patients,
relatively higher for streptomycin (27 mg/kg body-
weight). Considering the results at three months,
98 (74 %) of 132 patients in the Medical Research
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Council study yielded a negative culture com-
pared with 62 (82 %) of 76 SHTW patients in
the present study. Further, 12 (9 %) patients
in the former compared with only three (4 %)
in the latter developed resistance to isoniazid by
this time. The better results in the present study
may be due to the high dose of isoniazid, and
perhaps the relatively high dosage of strepto-
mycin, rather than to the effect of giving both
drugs together intermittently. The findings of
Gangadharam et al. (1961b) that high peak serum
concentrations of isoniazid play a more important
role in the response to treatment than the main-
tenance of a continuous inhibitory level of iso-
niazid lend support to such an inference.
TOXICITY
Isoniazid toxicity occurred in two of 78 SHTW
patients (convulsions in one and peripheral neuro-
pathy in the other) as compared with none of 70
PH patients. Both patients were treated success-
fully with 6 mg of pyridoxine twice weekly with-
out reducing the dosage of isoniazid.
With regard to toxic reactions to the drug used
with isoniazid, spontaneous complaints of giddi-
ness were made by 27 (35 %) of 78 SHTW
patients ; the giddiness, which usually occurred
half an hour to two hours after the injection,
was mild and of short duration. Further, it is
unlikely that the complaints were always due
to streptomycin as similar complaints were made
by eight (11 %) of the 70 PH patients, in whom
they were less likely to have been recorded.
None of the SHTW patients had chemotherapy
terminated on account of toxicity, but for five
who complained of giddiness, the dosage of
streptomycin was reduced to approximately 15
mg/kg body-weight, for three of them for the
rest of the year and for two for a short period
only. In contrast, three (4 %) of the 70 PH
patients had chemotherapy terminated on account
of hypersensitivity reactions to PAS ; other mani-
festations of PAS toxicity among patients in this
series were unimportant.
It is of interest to compare the incidence of
isoniazid toxicity in this study with that in patients
in our earlier studies who did not receive any
effective prophylactic supplement. Of 60 patients
in the earlier studies who received approximately
14 mg/kg body-weight of isoniazid daily, 18 (30 %)
developed isoniazid toxicity (Tuberculosis Chemo-
therapy Centre, 1963b) as compared with only
two (3 %) of those who received the same dosage
twice weekly in the present study; on the other
hand, only one of 440 patients who received
isoniazid (either alone or in combination with
sodium PAS) in a larger total weekly dosage than
in the present study–namely, 4 to 6 mg/kg
a day (Tuberculosis Chemotherapy Centre, 1959,
1960 and the present report)–developed toxicity.
There is a similar finding in respect of strepto-
mycin toxicity ; thus, of 69 patients who received
a uniform dosage of 1 g of streptomycin daily
in an earlier study (Velu et al., 1964), 24 (35 %)
had to have the dosage reduced to approxi-
mately 15 mg/kg body-weight as compared with
five (6 %) of 78 patients who received the same
dosage twice weekly in the present study, and
four (6 %) had to have their treatment termin-
ated on account of toxicity in the earlier study
as compared with none in the present study. Thus,
there has apparently been a considerable reduc-
tion in the incidence of toxic reactions, both to
isoniazid and to streptomycin, by reducing the
frequency of drug-administration from daily to
twice weekly (keeping the dose the same).
It is likely that even the small amount of iso-
niazid toxicity occurring with the intermittent regi-
men can be prevented by giving 6 mg of pyri-
doxine twice weekly, since it has been shown
that, when given daily in this dosage with 14
mg/kg of isoniazid daily, pyridoxine prevents. peri-
pheral neuropathy (Tuberculosis Chemotherapy
Centre, 1963b) ; furthermore, both patients who
showed isoniazid toxicity in the present study
responded to 6 mg of pyridoxine given twice
weekly. The interpretation of the findings on
streptomycin toxicity is less clear and special
attention is therefore being paid in a current
study to the assessment and prevention of such
toxicity.
CO-OPERATION
With regard to the co-operation obtained in
the two series, seven SHTW patients became so
uncooperative as to stop treatment against medical
advice. (In four of these, streptomycin toxicity
might have been a contributory factor.) As might
be expected, these patients were more irregular,
even before they stopped treatment, than the 71
who remained on their prescribed chemotherapy.
The latter patients attended on the appointed
day or earlier on 87 % of the occasions, were late
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by one day or more on 5 % of the occasions
and missed an attendance altogether on 8 % of
the occasions. The late and missed attendances,
which caused extra work for the Centre’s staff,
became more frequent towards the end of treat-
ment ; thus the proportion of patients who, on
25 % or more of the occasions, attended after
the appointed day or did not attend at all in
each of the four quarters of the year were 4 %,
13%, 19% and 31 %, respectively. Of the PH
patients, only one became so uncooperative as
to stop treatment; however, 72 % of the re-
mainder were found to be irregular in taking
their drugs on one or more occasions, as assessed
by urine test results.
It should be remembered that the SHTW
patients had to attend the Centre twice a week
and receive an injection of streptomycin; thus
they came under the special attention of the
Centre’s staff every time they missed a scheduled
injection ; on the other hand, the PH patients had
to attend only once a week for a supply of the
drug, and it would thus have been easy for them
to omit doses without the Centre’s staff neces-
sarily becoming aware of it. It is therefore diffi-
cult to compare the acceptability of the supervised
intermittent regimen and the unsupervised daily
regimen ; however, despite the irregularities
observed, both regimens proved sufficiently robust
to achieve high rates of therapeutic success.
CONCLUSION
Summarizing the findings, the SHTW regimen
was therapeutically effective ; the incidence of
temporary giddiness was rather high but this
appeared to have no long-term importance or
lasting effects, nor did it appear unduly to affect
 the co-operation of the patients. However, because
of the uncertain significance of the complaints
of giddiness in the present study, special atten-
tion is being paid in a current trial to investi-
gating the side-effects and the acceptability of
intermittent regimens which include streptomycin
injections.
The success of intermittent chemotherapy in
this trial has suggested a new method of treat-
ment and possibly of the control of tuberculosis
in developing countries – namely, changing the
regimen from the present daily self-administration
to intermittent and fully supervised administration.
Although the twice-weekly regimen in this study
has been found to be successful, a regimen with
a smaller dosage of streptomycin and with longer
intervals between the doses would offer still
further advantages ; it might be not only less
toxic and more acceptable to the patients, thus
leading to their greater co-operation, but also
more economical and easier to apply in mass
treatment. Further studies along these lines are
at present in progress at the Centre.
XI. SUMMARY
1. One hundred and sixty-five South Indian SHTW series :
patients with pulmonary tuberculosis were allo- Streptomycin 27.0 mg/kg body-weight
cated by a random procedure to ambulatory (range 18.2-53.7 mg/kg)
out-patient treatment with streptomycin plus
isoniazid given together under supervision twice
Isoniazid 13.9 mg/kg body-weight
weekly (SHTW series, 83 patients) or to a stand-
(range 12.5-16.1 mg/kg)
ard unsupervised regimen of PAS plus isoniazid PH series :
for daily self-administration (PH series, 82 PAS 0.22 g/kg body-weight
patients). (range 0.18-0.32 g/kg)
2. The dosages of the drugs for patients Isoniazid 4.4 mg/kg body-weight
weighing 100 lb (45.5 kg) were 1 g streptomycin (range 3.7-6.3 mg/kg)
plus 650 mg of isoniazid in a single dose for the
SHTW regimen and 10 g of PAS (sodium) plus
3. Fifteen patients (four SHTW, 11 PH) were
excluded from the main analysis because they
200 mg of isoniazid in two divided doses for
the PH regimen.
had resistant organisms on admission to the study.
There remained 79 SHTW and 71 PH patients
in the main analysis who (a) had, on admission,
The mean initial dosages were : organisms sensitive to isoniazid and streptomycin,
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(b) had had no previous chemotherapy apart from
eight, who had had up to two weeks’ chemo-
therapy and (c) followed the allocated regimen
for 12 months, apart from minor variations,
unless it was terminated owing to death, deteriora-
tion, toxicity or non-cooperation.
4. The clinical, radiographic and bacterio-
logical condition of the patients in the two series
was similar at the time of admission to treatment.
5. During the year there were four deaths,
three (two SHTW, one PH) from pulmonary
tuberculosis and one (PH) from a non-tuberculous
condition ; serious radiographic deterioration
necessitating termination of chemotherapy oc-
curred in one patient in each series.
6. At one year, 94 % of 72 SHTW and 85 %
of 66 PH patients had bacteriologically quiescent
disease or disease of doubtful status. On including
the seven uncooperative patients (six SHTW, one
PH) whose response could be assessed, the pro-
portions with favourable response became 92 %
of 78 SHTW patients and 84 % of 67 PH patients.
7. At 12 months, single collection specimens of
sputum were negative on culture for 94 % of 72
SHTW and 89 % of 66 PH patients.
8. The majority of patients showed at least
moderate radiographic improvement over the
year-namely, 92 % of 72 SHTW and 94 % of
66 PH patients. Cavitation disappeared in 24 %
of 70 SHTW patients and 21 % of 63 PH patients.
9. Three (4 %) of 70 PH patients had their
originally prescribed chemotherapy terminated
because of cutaneous hypersensitivity reactions to
PAS for which they could not be desensitized.
None of 78 SHTW patients had chemotherapy
terminated on account of toxicity although 17
(22%) spontaneously complained of giddiness on
one occasion and 10 (13%) on two or more occa-
sions during the year; five of the latter had their
dosage of streptomycin reduced to 15 mg/kg body-
weight. Two (3 %) patients (both SHTW) deve-
loped toxicity to isoniazid, one having convulsions
and the other peripheral neuropathy ; both res-
ponded to 6 mg of pyridoxine given with each
dose of isoniazid.
10. Seven (9 %) SHTW patients and one
(1 %) PH patient became very uncooperative and
stopped treatment during the year ; this may have
been due partly to toxic effects of streptomycin
in four SHTW patients and to reasons uncon-
nected with the regimens in three other patients
(two SHTW, one PH) ; the remaining SHTW
patient stopped treatment for no apparent reason.
11. Lesser degrees of non-cooperation, mani-
fested by irregularities in taking the prescribed
chemotherapy, occurred frequently in both series.
Thus, only 10 % of the SHTW patients received
all of their prescribed chemotherapy during the
year, and as many as 28 % failed to receive their
treatment on 10 % or more of the occasions. In
the PH series, 72 % of the patients were irregular
in taking their drug at some time or other, includ-
ing 19 % who were irregular on at least a quarter
of the occasions. However, there was no evidence
that these irregularities were associated with un-
favourable response to treatment.
12. The encouraging results of this trial sug-
gest a possible change in the orientation of drug
administration for tuberculosis in developing
countries. Further investigations are in progress
at the Centre.
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RÉSUMÉ
Poursuivant leurs études sur le traitement de la trôlé, institué pour comparer les résultats de deux
tuberculose, les chercheurs du Centre chimiothéra- regimes thérapeutiques : le premier, bi-hebdomadaire
pique de la Tuberculose, de Madras, exposent dans et surveillé, le second, quotidien, non surveillé.
cet article les résultats de l’essai thérapeutique con- Dans le premier, 165 malades de I’Inde méridio-
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nale atteints de tuberculose pulmonaire ont été ré-
partis en deux groupes aléatoires: a) 83 malades
recevant en dispensaire, deux fois par semaine et sous
surveillance, 1 g de streptomycine et 650 mg d’isonia-
zide en une seule dose (regime SHTW) ; b) 82
malades absorbant eux-mêmes, et sans surveillance,
10 g de PAS et 200 mg d’isoniazide, répartis en deux
doses (série PH). Ces dosages correspondaient à des
sujets pesant 45,5 kg.
Quinze malades (4 SHTW et 11 PH) n’ont pas été
pris en considération dans l’analyse générale, car, au
debut du traitement, ils présentaient des bacilles ré-
sistants. Il restait donc 79 malades SHTW et 71 PH
qui a) étaient infectés par des bacilles sensibles à
l’isoniazide et à la streptomycine ; b) n’avaient pas
subi de traitement chimiothérapique antérieur, si ce
n’est 8 d’entre eux qui avaient reçu des médicaments
pendant 2 semaines au plus ; c) ont poursuivi leur
regime thérapeutique pendant 12 mois sauf quelques
minimes derogations, à moins que la mort, l’aggrava-
tion, certains effets toxiques ou l’indiscipline, y ait
mis prématurément terme. Les données cliniques,
radiologiques et bactériologiques étaient à peu près les
mêmes pour les malades des 2 séries.
Au cours de l’année, il y eut 4 décès, 3 par tuber-
culose pulmonaire (2 SHTW et 1 PH) et 1 (PH) d’une
maladie non tuberculeuse ; une aggravation révélée
par la radiographie nécessita l’interruption du traite-
ment chez 1 malade de chaque série.
A la fin de l’année d’essai, 94 % des 72 malades
SHTW et 85 % des 66 malades PH avaient atteint
le stade de quiescence bactériologique ou d’état « in-
certain » de la maladie. Si l’on tient compte des 7
malades (6 SHTW, 1 PH) indisciplinés, on obtient une
réponse favorable chez 92 % de 78 malades SHTW
et 84 % de 67 malades PH.
Après 12 mois, les crachats, prélevés une seule fois,
ont donné 94 % de cultures negatives (sur 72 SHTW)
et 89 % (sur 66 PH).
La plupart des malades présentaient une améliora-
tion radiologique fût-elle modeste, soit 92% des
72 SHTW et 94 % des 66 PH. Les cavités ont disparu
chez 24 % des 70 malades SHTW et chez 21 % des
malades PH qui présentaient des cavités au début
de l’essai.
Chez 3 des 70 malades PH (4 %), on a dû inter-
rompre l’administration de médicaments, par suite
de l’hypersensibilité cutanée au PAS qui n’a pu être
vaincue. Les effets toxiques n’ont pas entraîné d’in-
terruption du traitement dans la série des 78 malades
SHTW, bien que 17 d’entre eux (22 %) se plaignirent
de vertiges une fois, et 10 (13 %) deux fois ou plus.
Cinq de ces derniers reçurent une dose de strepto-
mycine moindre, soit 15 mg par kg de poids corporel.
Deux malades SHTW (3 %) présentèrent des phé-
nomènes de toxicité due à l’isoniazide, l’un ayant des
convulsions, l’autre une neuropathie périphérique ;
les deux se remirent, à la suite de l’administration
de 6 mg de pyridoxine avec chaque dose d’isoniazide.
Sept malades SHTW (9 %) et 1 malade PH (1 %),
sérieusement indisciplines, interrompirent le traite-
ment au cours de l’année, ce qui, chez 4 malades
SHTW au moins pourrait s’expliquer par les effets
toxiques de la streptomycine.
Des irrégularités dans la prise des médicaments
furent fréquentes dans les deux series. C’est ainsi que
10 % seulement des malades SHTW ont accompli
leur cure therapeutique complete, d’une année, et
28 % ont manqué leur tour une fois sur dix ou plus.
Dans la série PH, 72 % des malades ont négligé la
prise du medicament une fois ou l’autre ; 19 % une
fois sur quatre. 11 ne semble pas que ces irrégulari-
tés puissent être mises en relation avec les réponses
défavorables au traitement.
Les résultats encourageants de cet essai suggèrent
une réorientation des principes d’administration des
médicaments antituberculeux dans les pays en voie
de développement. L’étude de la question se poursuit.
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